A Delphi consensus statement of the Neuropathic Pain Special Interest Group of the Italian Neurological Society on pharmacoresistant neuropathic pain
read more
Citations
Chemotherapy-induced peripheral neuropathy: part 1-current state of knowledge and perspectives for pharmacotherapy.
Pharmacotherapeutic Options for Managing Neuropathic Pain: A Systematic Review and Meta-Analysis.
Diagnosis and treatment of Chiari malformation type 1 in children: the International Consensus Document.
Posterior-superior insular deep transcranial magnetic stimulation alleviates peripheral neuropathic pain - A pilot double-blind, randomized cross-over study.
Modulation of the N13 component of the somatosensory evoked potentials in an experimental model of central sensitization in humans.
References
Core outcome domains for chronic pain clinical trials: IMMPACT recommendations.
Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis.
Prevalence of chronic pain with neuropathic characteristics in the general population
Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendations
What decline in pain intensity is meaningful to patients with acute pain
Related Papers (5)
A review of Neuropathic Pain: From Guidelines to Clinical Practice.
Frequently Asked Questions (9)
Q2. How long does it take to improve a patient's PGIC?
While the analgesic effects of antidepressants on pain manifest in a few days to 1 week, the effects on depression and quality of life take approximately 2 to 4 weeks [14], thus possibly having late influence on the PGIC.
Q3. What are the main issues that the participants indicated in the meeting?
Concerning the influence of comorbidities, the participants indicated three main issues:the patient compliance and adherence to therapy, psychiatric comorbidities, and patient’s genotype influencing the drug effectiveness.
Q4. Who received honoraria for speaking at symposia?
Andrea Truini received honoraria for speaking at symposia or research financial supports from Alpha-Sigma, Angelini, Epitech, FB Health, and Pfizer.
Q5. How long does it take to get to the proper dosage?
Drugs used for treating neuropathic pain are usually carefully titrated for minimizing adverse events, and the adequate dosage is reached after several days or weeks.
Q6. How long should a drug be considered insufficient?
In the definition of pharmacoresistance the authors indicated that the minimal duration of treatment necessary to consider the drug insufficient should be of at least 1 month after titration.
Q7. What were the participants’ suggestions for additional treatments?
Some participants indicated among possible useful treatments cognitive and behavioral therapy, physiotherapy, acupuncture, relaxation, and nutritional supplements.
Q8. Who received an unconditioned support from Pfizer?
The face-to-face meeting was held during the congress of the Italian Society of Clinical Neurophysiology, receiving an unconditioned support by Pfizer.
Q9. Who is the primary target user of the Delphi definition of pharmacoresistant neuropathic?
Other target users are clinical researchers because adopting a consensus definition might help for selecting patients in pharmacological trials.